‫מחלת אלצהיימר‬
‫טיפול במעכבי כולין אסטרז ובממנטין במחלת אלצהיימר‬
1. CP Ferri, M Prince, Brayne et al. Alzheimer's Disease International. Global
prevalence
of
dementia:
a
Delphi
consensus
study.
Lancet,
2005;366:2112–2117
2. World Health Report 2003—Shaping the futureWHO, Geneva (2003)
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol. 1991;82(4),239–259.
4. Morris R, Mucke L. Alzheimer's disease: A needle from the haystack.
Nature.200616;440(7082):284-5
5. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease:
a dual pathway hypothesis. Neuron. 2008;60(4):534-42.
6. Meraz-Ríos MA, Lira-De León KI, Campos-Peña V, et al. Tau oligomers
and aggregation in Alzheimer's disease. J Neurochem. 2010;112(6):135367.
7. Takashima A. Amyloid-beta, tau, and dementia. J Alzheimers Dis.
2009;17(4):729-36.
8. Corder
EH,
Saunders
AM,
Strittmatter
WJ,et
al.Gene
dose
of
apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late
onset families. Science. 1993;261(5123):921-3
9. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments
for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168-74
10. Hardy J, Myers A, Wavrant-De Vrieze F. Problems and solutions in the
genetic analysis of late-onset Alzheimer's disease. Neurodegener Dis.
2004;1(4-5):213-7.
11. Jonsson T, Atwal JK, Steinberg S et al. A mutation in APP protects against
Alzheimer's
disease
and
age-related
cognitive
decline.
Nature.
2012;488(7409):96-9.
12. Mesulam MM, Hersh LB, Mash DC, et al. Differential cholinergic
innervation within functional subdivisions of the human cerebral cortex: a
choline acetyltransferase study. J. Comp. Neurol.1992;318(3),316–328.
1
13. Carnes KM, Fuller TA, Price JL. Sources of presumptive
glutamatergic/aspartatergic afferents to the magnocellular basal forebrain
in the rat. J Comp Neurol. 1990;302(4):824-52.
14. Zilles K, Werner L, Qü M, Schleicher A, Gross G. Quantitative
autoradiography of 11 different transmitter binding sites in the basal
forebrain region of the rat-evidence of heterogeneity in distribution
patterns. Neuroscience. 1991;42(2):473-81.
15. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis
of Alzheimer’s disease: a review of progress. J. Neurol. Neurosurg.
Psychiatr. 1999;66(2):137–147
16. Bowen DM, Benton JS, Spillane JA, et al. Choline acetyltransferase
activity and histopathology of frontal neocortex from biopsies of demented
patients. J. Neurol. Sci.1982;57(2–3),191–202.
17. Davis KL, Mohs RC, Marin D et al. Cholinergic markers in elderly patients
with early signs of Alzheimer disease. JAMA. 1999; 281(15),1401–1406.
18. Neary D, Snowden JS, Mann DM et al. Alzheimer’s disease: a correlative
study. J. Neurol. Neurosurg. Psychiatr.1986;49(3),229–237.
19. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase
inhibitors used in the treatment of Alzheimer’s disease: the relationship
between pharmacological effects and clinical efficacy. Drugs Aging.
2004;21(7),453–478.
20. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane
Database Syst Rev. 2006
21. Kuhl DE, Minoshima S, Frey KA, et al. Limited donepezil inhibition of
acetylcholinesterase measured with positron emission tomography in living
Alzheimer cerebral cortex. Ann Neurol. 2000;48(3):391-5.
22. Farlow MR, Lilly ML; ENA713 B352 Study Group. Rivastigmine: an openlabel, observational study of safety and effectiveness in treating patients
with Alzheimer’s disease for up to 5 years. BMC Geriatr. 2005;5:3.
2
23. Tariot PN, Farlow MR, Grossberg GT, et al . Memantine treatment in
patients with moderate to severe Alzheimer disease already receiving
donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.
24. Doody RS, Geldmacher DS, Gordon B, et al.; Donepezil Study Group.
Open-label, multicenter, phase 3 extension study of the safety and efficacy
of donepezil in patients with Alzheimer disease. Arch Neurol.
2001;58(3):427-433.
25. Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of
donepezil in the treatment of Alzheimer’s disease: final analysis of a US
multicentre open-label study. Eur Neuropsychopharmacol.
2000;10(3):195-203.
26. Grossberg G, Irwin P, Satlin A et al. Rivastigmine in Alzheimer disease:
efficacy over two years. Am J Geriatr Psychiatry. 2004;12(4):420-431.
27. Lyketsos CG, Reichman WE, Kershaw P, et al. Long-term outcomes of
galantamine treatment in patients with Alzheimer disease. Am J Geriatr
Psychiatry. 2004;12(5):473-482.
28. Raskind MA, Peskind ER, Truyen L, et al. The cognitive benefits of
galantamine are sustained for at least 36 months: a long-term extension
trial. Arch Neurol. 2004;61(2): 252-256.
29. Khang P, Weintraub N, Espinoza RT. The use, benefits, and costs of
cholinesterase inhibitors for Alzheimer’s dementia in long-term care: are
the data relevant and available? J Am Med Dir Assoc. 2004;5(4):249-255.
30. da Costa Dias FL, da Silva RM, de Moraes EN, Caramelli P.
Cholinesterase Inhibitors Modulate Autonomic Function in Patients with
Alzheimer's Disease and Mixed Dementia. Curr Alzheimer Res. 2013
31. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of
high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in
moderate to severe Alzheimer's disease: A 24-week, randomized, doubleblind study. Clin Ther. 2010;32(7):1234-51.
32. Cummings J, Froelich L, Black SE, et al. Randomized, double-blind,
parallel-group, 48-week study for efficacy and safety of a higher-dose
rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. Dement Geriatr
Cogn Disord. 2012;33(5):341-53.
3
33. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J.
Neurochem.1984;42(1),1–11.
34. Auerbach JM, Segal M. A novel cholinergic induction of long-term
potentiation in rat hippocampus. J. Neurophysiol.1994;72(4),2034–2040.
35. Greenamyre JT, Maragos WF, Albin RL et al. Glutamate transmission and
toxicity in Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol.
Psychiatry.1998;12(4),421–430.
36. Snyder EM, Nong Y, Almeida CG et al. Regulation of NMDA receptor
trafficking by amyloid-b. Nat. Neurosci.2005;8(8),1051–1058.
37. Danysz W, Parsons CG. Alzheimer’s disease, β-amyloid, glutamate,
NMDA receptors and memantine – searching for the connections. Br. J.
Pharmacol.2012;167(2),324–352.
38. Procter AW, Palmer AM, Francis PT et al. Evidence of glutamatergic
denervation and possible abnormal metabolism in Alzheimer’s disease. J.
Neurochem.1998;50(3),790–802.
39. Francis PT. Altered glutamate neurotransmission and behaviour in
dementia: evidence from studies of memantine. Curr. Mol. Pharmacol.
2009;2(1),77–82.
40. Reisberg B, Doody R, Stöffler A et al. Memantine Study Group.
Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J.
Med.2003;348(14),1333–1341.
41. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in
patients with moderate to severe Alzheimer disease already receiving
donepezil: a randomized controlled trial. JAMA. 2004;291(3),317–324.
42. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in
moderate to severe Alzheimer’s disease: a meta-analysis of randomised
clinical trials. Dement. Geriatr. Cogn. Disord.2007;24(1),20–27.
4
43. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in
patients with moderate to severe Alzheimer’s disease by memantine: a
pooled data analysis. Int. J. Geriatr. Psychiatry.2008;23(5),537–545).
44. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural
symptoms in Alzheimer’s disease patients: an analysis of the
Neuropsychiatric Inventory (NPI) data of two randomised, controlled
studies. Int. J. Geriatr. Psychiatry.2005;20(5),459–464.
45. Cummings JL, Schneider E, Tariot PN, Graham SM; Memantine MEMMD-02 Study Group. Behavioral effects of memantine in Alzheimer
disease patients receiving donepezil treatment. Neurology.2006;67(1),57–
63.
46. Choi SH, Park KW, Na DL, et al; Expect Study Group. Tolerability and
efficacy of memantine add-on therapy to rivastigmine transdermal patches
in mild to moderate Alzheimer's disease: a multicenter, randomized, openlabel, parallel-group study. Curr Med Res Opin. 2011;27(7):1375-83.
47. Nyakas C, Granic I, Halmy LG, et al. The basal forebrain cholinergic
system in aging and dementia. Rescuing cholinergic neurons from
neurotoxic amyloid-β42 with memantine. Behav. Brain
Res.2011;221(2),594–603.
48. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in
patients with moderate to severe Alzheimer’s disease by memantine: a
pooled data analysis. Int J Geriatr Psychiatry. 2008;23:537-545.
49. Vidal JS, Lacombe JM, Dartigues JF, et al. Evaluation of the impact of
memantine treatment initiation on psychotropics use: a study from the
French national health care database. Neuroepidemiology. 2008;31:193200
50. Wilkinson D, Andersen HF. Analysis of the effect of memantine in
reducing the worsening of clinical symptoms in patients with moderate to
severe Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;24(2):138145.
5
51. Francis PT, Parsons CG, Jones RW. Rationale for combining
glutamatergic and cholinergic approaches in the symptomatic treatment of
Alzheimer's disease. Expert Rev Neurother. 2012;12(11):1351-65.
52. Lopes JP, Tarozzo G, Reggiani A, et al. Galantamine potentiates the
neuroprotective effect of memantine against NMDA-induced excitotoxicity.
Brain Behav. 2013;3(2):67-74.
53. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the
concomitant use of memantine with cholinesterase inhibition in Alzheimer
disease. J Neurol Neurosurg Psychiatry. 2009;80:600-607.
54. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for
moderate-to-severe Alzheimer's disease. N Engl J Med.
2012;366(10):893-903.
55. Tariot PN. Cessation of donepezil is associated with clinical decline in
patients with moderate-to-severe Alzheimer's disease compared to
continuation of donepezil or addition or substitution of memantine. Evid
Based Med. 2013;18(2):62-3.
6